Comparative Pharmacology
Head-to-head clinical analysis: ICLUSIG versus XALKORI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLUSIG versus XALKORI.
ICLUSIG vs XALKORI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
Selective tyrosine kinase inhibitor targeting ALK, ROS1, and MET, inhibiting downstream signaling pathways (PI3K/AKT, MAPK/ERK) leading to reduced tumor cell proliferation and survival.
45 mg orally once daily with or without food.
250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Terminal elimination half-life is approximately 72 hours (range 47-108 hours) in patients, supporting once-daily dosing.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Primarily hepatic metabolism, with 53% of the dose recovered in feces (mostly as metabolites) and 22% in urine (1.1% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor